CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the Company plans to participate in the Raymond James 2021 Human Health Innovation Conference.

CareDx to Participate in Raymond James 2021 Human Health Innovation Conference

Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development

CareDx congratulates Hannah Valantine for her State of the Art Lecture at ATC on Transplant Equity

KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled

CareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through ARTS Surveillance

Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure

CareDx Presents Groundbreaking AlloSure® Data at the 2021 American Transplant Congress

Partnership with OrganX to develop decision support systems Partnership with OrganX to develop decision support systems

CareDx Advances Artificial Intelligence in Transplantation

Bloom Energy

NetApp

APA Corporation

AvalonBay Communities

Blade Air Mobility

Enphase Energy

With the trading day about halfway over, the markets were sliding, with the tech sector getting the worst of it.

APA, Bloom Energy, NetApp and More Thursday Afternoon Analyst Calls

Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients

CareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare

Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs

CareDx Announces Strategic Minority Investment in Miromatrix

CareDx, Inc (CDNA) is dominating the organ transplant diagnostic solutions market, growing at 40% annually.

CareDx: The Market Leader In Organ Transplant Diagnostic Solutions/Software, With Strong Growth Prospects

CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement

CareDx to Participate in AAKP and George Washington University Global Summit on Kidney Disease Innovations

CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.

This Under-the-Radar Healthcare Company Quietly Surged During the Pandemic

CareDx, Inc.'s (CDNA) CEO Reginald Seeto on Q1 2021 Results - Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of 1500.00% and 10.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Q1 Earnings and Revenues Surpass Estimates

Strong start to 2021, raising full year guidance Strong start to 2021, raising full year guidance

CareDx Reports First Quarter 2021 Results

Renowned transplant clinicians to present 15 heart abstracts at ISHLT Renowned transplant clinicians to present 15 heart abstracts at ISHLT

CareDx to Present New Heart Transplant Data at the International Society for Heart and Lung Transplantation Annual Meeting

Current Medicare coverage for CareDx services remains unchanged under the new universal coverage policy Current Medicare coverage for CareDx services remains unchanged under the new universal coverage policy

Palmetto MolDx Issues Foundational Coverage for Molecular Testing in Solid Organ Allograft Rejection

Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual Meeting Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual Meeting

CareDx to Debut Multicenter Data on AlloSure® Lung, an Analytically and Clinically Validated Biomarker of Graft Injury for Lung Transplant Patients

SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

CareDx to Report First Quarter 2021 Financial Results

Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians

CareDx Showcases Transplantation Innovation and Leadership in Europe at EFI 2021

Company to showcase its latest integrated solutions for improving care across the whole transplant journey Company to showcase its latest integrated solutions for improving care across the whole transplant journey

CareDx to Present at UNOS Transplant Management Forum

Initial projects underway for global pharmaceutical company Initial projects underway for global pharmaceutical company

CareDx Announces New HLA Typing Service Offering for Research Purposes

CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program

CareDx to Participate in National Kidney Foundation 2021 Spring Clinical Meetings

Natera

Veracyte

These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.

3 Cancer Diagnostic Monster Stocks on Sale

CareDx Builds for the Future by Investing in Talent CareDx Builds for the Future by Investing in Talent

CareDx Enhances Leadership Team with Key Appointments

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the appointment of Ankur Dhingra as the company's new Chief Financial Officer (CFO) effective March 25, 2021. As CFO, Ankur will lead CareDx's global finance organization including treasury, tax, and other corporate functions, and report directly to President and Chief Executive Officer Reg Seeto.

News for CareDx Stock (CDNA)